Inhibrx Biosciences Inc Stock Price, News & Analysis

Inhibrx (Nasdaq: INBX) reported positive topline results from the registrational ChonDRAgon study of ozekibart (INBRX-109) in advanced/metastatic chondrosarcoma and provided interim expansion-cohort updates in colorectal cancer and Ewing sarcoma.

Key results: PFS HR 0.479 (P<0.0001), median PFS 5.52 vs 2.66 months; disease control rate 54% vs 27.5%. CRC combo (FOLFIRI) interim: ORR 23%, DCR 92% (26 evaluable). Ewing combo (IRI/TMZ) interim: ORR 64%, DCR 92% (25 evaluable). One early hepatotoxicity-related fatality occurred; hepatic AEs 11.8% vs 4.5% placebo. Company plans a BLA filing in Q2 2026.

Inhibrx (Nasdaq: INBX) will webcast topline results from the registrational ChonDRAgon study of ozekibart (INBRX-109) versus placebo in advanced/metastatic unresectable chondrosarcoma on Thursday, October 23, 2025 at 1:30 p.m. PT.

The company will also provide updates on two expansion cohorts: ozekibart plus FOLFIRI in late-line colorectal cancer and ozekibart with irinotecan and temozolomide in refractory Ewing sarcoma. Investors can join via webcast or listen by dial-in; the webcast will be available for 60 days after the event and the corporate presentation will be updated in the Investors section of the company website.

Inhibrx (NASDAQ:INBX) reported Q2 2025 financial results following its spin-off from Former Parent and the $2.0B INBRX-101 sale to Sanofi in May 2024. The company ended Q2 with $186.6 million in cash, down from $216.5M in Q1. Revenue was $1.3 million, up from $0.1M in Q2 2024.

R&D expenses decreased to $22.3 million from $67.6M, while G&A expenses dropped to $6.4 million from $93.4M. The company reported a net loss of $28.7 million ($1.85 per share) compared to net income of $1.9B in Q2 2024. Two key clinical trials are progressing with data readouts expected in late 2025: the ozekibart Phase 2 trial for chondrosarcoma and INBRX-106 Phase 2/3 trial for head and neck cancer.

Inhibrx (NASDAQ: INBX) reported its Q1 2025 financial results, showing a net loss of $43.3 million ($2.80 per share), an improvement from the $78.7 million loss in Q1 2024. The company's cash position strengthened to $216.5 million, up from $152.6 million, boosted by a $100 million loan from Oxford Finance.

Following the sale of INBRX-101 to Sanofi and subsequent spin-off in May 2024, Inhibrx now focuses on two clinical programs: INBRX-109 and INBRX-106. Key data readouts are expected in 2025, including Phase 2 trial results for INBRX-109 in chondrosarcoma (Q3) and Phase 2 data for INBRX-106 in head and neck cancer (Q4).

Operating expenses decreased significantly, with R&D expenses falling to $36.9 million from $63.9 million, and G&A expenses reducing to $6.0 million from $10.0 million year-over-year.

Inhibrx Biosciences (NASDAQ: INBX) announced key leadership changes as co-founder and CSO Dr. Brendan Eckelman departs to establish a new private biotech company. The company has appointed Dr. Carlos Bais, current Executive VP of Translational Sciences, as the new CSO, and promoted David Matly to President while maintaining his existing roles.

As part of the transition, Inhibrx has entered into an exclusive license agreement with Dr. Eckelman's new venture for certain unused technologies, including provisions for upfront payment and future development milestones. David Matly, who played a important role in Inhibrx's $2.2B asset sale of INBRX-101 to Sanofi in 2024, will oversee clinical development, R&D, technical operations, and regulatory affairs in his expanded role.

Inhibrx (Nasdaq: INBX) reported its Q4 and fiscal year 2024 financial results following its spin-off from Former Parent and sale of INBRX-101 to Sanofi in May 2024. The company secured a $100M loan from Oxford Finance in January 2025, with potential for additional $50M funding.

Key clinical developments include promising interim data from ozekibart (INBRX-109) Phase 1 trial in colorectal cancer, showing complete response in one patient, partial responses in three, and stable disease in six patients. The company has initiated a new expansion cohort for up to 50 patients.

Financial highlights:

• Cash position: $230.5M as of February 2025
• Q4 2024: Net loss of $47.9M ($3.09 per share)
• FY 2024: Net income of $1.7B ($114.01 per share)
• R&D expenses decreased to $33.4M in Q4 2024 from $82.1M in Q4 2023
• G&A expenses increased to $16.7M in Q4 2024 from $7.8M in Q4 2023

Inhibrx Biosciences (NASDAQ: INBX) has released preliminary data from its Phase 1 trial of ozekibart (INBRX-109) combined with FOLFIRI for treating advanced colorectal cancer. The trial showed promising results among 10 evaluated patients, including one complete response, three partial responses, and six stable disease cases. The study demonstrated durable disease control lasting ≥180 days in 46.2% of patients, with a median progression-free survival of 7.85 months.

Treatment-emergent adverse events related to ozekibart were reported in 84.6% of patients, mostly grade 1 or 2 in severity, with grade ≥3 events in 30.8% of patients. Common side effects included nausea, increased alanine aminotransferase, diarrhea, and fatigue. Based on these encouraging results, Inhibrx has initiated an expansion cohort to enroll up to 50 patients, with data expected in Q3 2025.

Inhibrx Biosciences (Nasdaq: INBX) has secured a five-year term loan facility of up to $150 million through a loan and security agreement with Oxford Finance The company received an initial term loan of $100 million on January 13, 2025, with an additional $50 million available subject to lenders' discretion.

The agreement includes interest-only payments until March 2028. As part of the deal, Inhibrx issued warrants to purchase 140,741 shares of common stock at $14.21 per share, representing 2% of the initial term loan value. Additional warrants will be issued with any future funding.

The financing aims to provide strategic flexibility for Inhibrx's INBRX-109 and INBRX-106 programs, which are currently in clinical trials with data readouts expected later in 2025.

Inhibrx Biosciences (INBX) reported Q3 2024 financial results, showing a net loss of $43.9 million ($2.84 per share) compared to $51.8 million ($4.39 per share) in Q3 2023. The company held cash and equivalents of $196.3 million as of September 30, 2024, down from $226.9 million in June 2024. R&D expenses increased to $38.9 million from $38.1 million year-over-year, mainly due to expanded clinical trials. G&A expenses remained stable at $7.9 million. The company has two ongoing clinical programs with expected data readouts within 12 months.